Invitrocue currently operates in Singapore and China

and is listed on Australian Securities Exchange under the ticker IVQ.

Welcome

Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases.

In 2016, the company expanded its work in liver disease to the field of oncology. The technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).

About Us

News & Events

25 Sep 2018
The 4th International Conference on Toxicity Testing Alternatives and Translational Toxicology & The 2nd Asian Congress on Alternatives @ Guangzhou

Date: October 11th, 2018; Thursday, Venue: Guangzhou Baiyun International Conference Center Prof Hanry Yu, co-founder of Invitrocue, will be giving a plenary presentation on: “Heterogeneity and solutions in cell-based models for in vitro toxicity testing applications”. Alternatives and translational toxicology have grown critically in modern toxicology and risk assessment. Meanwhile, alternatives are increasingly demanding for […]

Read More
13 Sep 2018
Oncology: The future of cancer treatment

Our international speakers will present the most important innovations and findings in the field of oncology. Happening on Monday, 1st October 2018, 9am – 3.45pm Venue: Klinikum rechts der Isar der Technischen Universität München Click to Download    

Read More
04 Sep 2018
Business updates

Business updates

Read More
13 Apr 2018
IVQ launches Personalised Cancer Screening Service Onco-PDO

Invitrocue launches world’s first commercial Personalised Cancer Screening Service: Onco-PDO™

Read More
13 Apr 2018
Invitrocue unveils novel cancer detection method, screens first customer in Singapore

Bio-analytic healthcare provider Invitrocue (ASX: IVQ), has advanced its proprietary cancer-detection test by screening its first commercial Onco-PDO customer in Singapore.

Read More
28 Feb 2018
Half Yearly Report and Accounts

Half Yearly Report and Accounts

Read More
26 Feb 2018
Grant from Northern Ireland to commercialize Onco-PDO

Invitrocue secures grant from Northern Ireland to commercialise Onco-PDO

Read More
23 Feb 2018
Investor Presentation

Investor presentation

Read More
20 Feb 2018
Change of Director’s Interest Notice – Jamie Khoo

Change of Director’s Interest Notice – Jamie Khoo

Read More
20 Feb 2018
Change of Director’s Interest Notice – Steven Fang

Change of Director’s Interest Notice – Steven Fang

Read More